Trials / Completed
CompletedNCT00044070
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion, and FLAIR Magnetic Resonance Imaging in Patients With Acute Ischemic Stroke
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the effects of a potential neuroprotectant compound, YM872, in the treatment of acute ischemic stroke. The study will determine if a 24-hour infusion of YM872, given within 6 hours of stroke onset, reduces the ischemic lesion volume as measured by MRI at 28 days after the infusion is given. The clinical effects of YM872 will also be determined by neurological function and disability scores at follow up visits through Day 90 of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM872 (zonampanel) |
Timeline
- Start date
- 2000-12-01
- Completion
- 2003-01-01
- First posted
- 2002-08-20
- Last updated
- 2006-04-03
Locations
89 sites across 6 countries: United States, Austria, Belgium, Canada, Germany, South Africa
Source: ClinicalTrials.gov record NCT00044070. Inclusion in this directory is not an endorsement.